Board Certified Pharmacotherapy Specialist (BCPS) Practice Exam

The Board Certified Pharmacotherapy Specialist (BCPS) Practice Exam is created by qualified educators and pharmacy-focused content professionals to give candidates a practical way to review advanced pharmacotherapy concepts before test day. This preparation resource contains 775 practice questions and answers with detailed explanations, written around patient cases, clinical decision-making, medication safety, monitoring, pharmacokinetics, calculations, and therapeutic problem-solving.

Rather than relying on simple definition-based questions, this BCPS exam prep is designed around the type of clinical reasoning pharmacists use when evaluating a patient’s medications, laboratory results, disease state, drug interactions, treatment response, and competing therapeutic risks.

BPS describes BCPS certification as validating advanced knowledge, skills, and experience needed to optimize medication safety and efficacy across diverse patients and practice settings. The current Pharmacotherapy Examination Content Outline is based on a formal job analysis and is intended to reflect the competencies required for contemporary pharmacotherapy practice.

How This BCPS Practice Test Helps You Prepare

Use realistic clinical questions to strengthen the decision-making skills needed for a challenging board certification examination.

• 775 BCPS-style multiple-choice questions and answers
• Detailed explanations for correct answers
• Patient case and clinical-vignette questions
• Medication selection and treatment optimization
• Adverse drug reaction recognition
• Drug-drug and drug-disease interactions
• Renal and hepatic dose adjustment
• Pharmacokinetic calculations and interpretation
• Laboratory and therapeutic drug monitoring
• Antimicrobial stewardship
• Cardiovascular and heart-failure pharmacotherapy
• Diabetes and endocrine management
• Critical care and acute-care scenarios
• Neurology and psychiatric pharmacotherapy
• Oncology and supportive-care concepts
• Anticoagulation and antiplatelet therapy
• Evidence-based medicine and clinical calculations

The questions are intended to help you identify weak areas, practice prioritizing clinical information, and become more comfortable making medication-related decisions under exam conditions.

What Is the BCPS Exam?

The Board Certified Pharmacotherapy Specialist (BCPS) examination is a specialty certification examination administered by the Board of Pharmacy Specialties (BPS) for pharmacists practicing across pharmacotherapy settings. BPS states that the BCPS target population includes pharmacists who optimize medication therapy and promote safe, appropriate, and economical medication use in diverse practice environments.

The examination is built from an Examination Content Outline developed through a formal job-analysis process. BPS explains that these outlines are reviewed approximately every five years so that examination competencies remain aligned with contemporary pharmacy practice.

What’s Included in This BCPS Exam Prep?

This practice resource is built for active studying rather than passive reading.

You’ll find:

• 750+ practice questions
• Four answer choices for each question
• Correct answer identified after each question
• Detailed clinical explanations
• Case-based pharmacotherapy scenarios
• Practical medication-management questions
• Calculation and interpretation questions
• Patient-specific treatment decisions
• Monitoring and follow-up questions
• Safety and adverse-effect scenarios
• Drug interaction questions
• Renal and hepatic impairment cases
• Evidence-based pharmacotherapy questions
• Exam-style distractors designed to test clinical judgment

The explanations are particularly useful when reviewing missed questions because they explain why the correct option is preferred and why the clinical situation changes the treatment decision.

BCPS Topics and Core Pharmacotherapy Areas Covered

The practice questions span the major areas candidates need to review for comprehensive pharmacotherapy preparation.

• Cardiovascular pharmacotherapy
• Heart failure
• Hypertension
• Arrhythmias
• Acute coronary syndromes
• Anticoagulation
• Antiplatelet therapy
• Infectious diseases
• Antimicrobial stewardship
• Diabetes mellitus
• Obesity and metabolic disease
• Endocrinology
• Nephrology
• Renal dose adjustment
• Pulmonary disease
• COPD and asthma
• Neurology
• Psychiatry
• Oncology
• Pain management
• Critical care
• Emergency pharmacotherapy
• Gastrointestinal disorders
• Rheumatology
• Hematology
• Transplant-related pharmacotherapy
• Geriatric pharmacotherapy
• Medication safety
• Pharmacokinetics
• Pharmacodynamics
• Therapeutic drug monitoring
• Drug interactions
• Adverse drug reactions
• Pharmacoeconomics
• Evidence-based medicine
• Biostatistics and clinical calculations

The goal is not simply to memorize drug facts. BCPS preparation requires the ability to connect patient characteristics + disease state + laboratory data + medication history + treatment goals and then select the most appropriate pharmacotherapy.

How We Created This BCPS Practice Exam

Each question was developed around a clinical problem rather than a basic recall prompt. The question set emphasizes the type of reasoning required when several treatment options appear reasonable but one is more appropriate because of the patient’s renal function, comorbidities, adverse-effect risk, laboratory findings, treatment goals, or current clinical status.

Questions also incorporate realistic variables such as:

• Kidney and liver function
• Age and body weight
• Medication adherence
• Laboratory abnormalities
• Drug interactions
• Contraindications and precautions
• Treatment failure
• Therapeutic response
• Adverse reactions
• Infection severity
• Hemodynamic status
• Cardiovascular and renal risk
• Patient-specific treatment goals

BPS itself notes that its examination content outlines are developed through job analysis involving subject-matter experts and validation among board-certified pharmacists.

Who Can Take the BCPS Exam?

BCPS certification is intended for eligible pharmacists who meet the requirements established by BPS. Applicants must satisfy the applicable education and practice-experience requirements before submitting their application. BPS states that all practice experience used for eligibility must be completed after pharmacist licensure or registration.

Eligibility pathways can involve pharmacy education and qualifying postgraduate practice or residency experience. Because requirements can change, candidates should verify the current BCPS eligibility criteria directly with BPS before applying.

BPS also states that residency completion and practice experience used for eligibility must fall within the applicable recent timeframe specified by its current requirements.

BCPS Exam Eligibility — Current Information

Before applying, candidates should confirm that they meet all current BCPS eligibility requirements.

The BPS application process requires candidates to:

• Meet the current BCPS education requirements
• Meet the applicable post-licensure practice or residency requirements
• Maintain appropriate pharmacist licensure or registration
• Provide required supporting documentation
• Submit the application through the MyBPS system
• Complete eligibility requirements before applying

BPS states that applicants upload documentation such as a current pharmacist license or registration and verification of qualifying practice experience. Approved candidates receive an authorization-to-test email containing information needed to schedule the examination.

Because BPS periodically updates eligibility pathways and examination policies, candidates should always confirm the requirements applicable to their intended examination date.

BCPS Exam Registration

BCPS applications are submitted online through the MyBPS Portal. BPS states that applicants create or use their existing MyBPS profile, select the certification application, upload required documentation, and submit payment. Applications are reviewed by BPS, with an eligibility decision generally communicated within 30 calendar days.

Once approved, candidates receive an authorization-to-test notification and can schedule through Pearson, which became BPS’s examination delivery provider beginning in 2026.

For 2026, BPS states that most certification programs use continuous testing, allowing approved candidates to select a testing session within their eligibility period. For continuous-testing authorizations issued after January 1, 2026, the eligibility period is 90 calendar days.

How the BCPS Exam Is Scored

BPS examinations use a scaled-score system, rather than simply reporting the percentage of questions answered correctly. BPS provides information about the passing standard, equating, scaled scores, and interpretation of score reports through its examination-scoring resources.

For continuously administered examinations, BPS introduced immediate preliminary pass/fail reporting beginning in January 2026. Candidates can see the preliminary outcome after completing the examination, while the official score report is made available through the MyBPS account within 45 calendar days.

Because the examination uses equating and scaled scoring, candidates should not interpret a practice-test percentage as a direct prediction of the official BCPS score.

BCPS Study Tips

A strong study plan should combine content review with repeated clinical-question practice.

• Start with the current BCPS Examination Content Outline.
• Build a study schedule around your weaker domains.
• Practice patient cases instead of relying only on flashcards.
• Review every missed question.
• Understand why each distractor is incorrect.
• Practice renal and hepatic dose adjustments.
• Review major drug interactions.
• Memorize high-yield monitoring parameters.
• Practice pharmacokinetic and biostatistical calculations.
• Review antimicrobial spectra and stewardship principles.
• Connect medications with major adverse effects.
• Revisit guidelines for frequently tested disease states.
• Complete timed question sets as the examination approaches.

BPS specifically recommends becoming familiar with the current Examination Content Outline because it serves as the blueprint for the certification examination.

BCPS Exam-Day Tips

The BCPS examination requires more than knowing the correct drug. You need to identify the most appropriate decision for the patient in front of you.

On exam day:

• Read the entire patient vignette before choosing an answer.
• Identify the actual question being asked.
• Pay attention to renal function and laboratory values.
• Look for contraindications and drug interactions.
• Distinguish urgent problems from routine problems.
• Eliminate clearly unsafe choices first.
• Do not overinterpret irrelevant information.
• Use clinical priorities when several answers appear reasonable.
• Keep calculations organized.
• Do not spend excessive time on one item.

BPS notes that examination items are answered in the order presented and candidates cannot return to previously answered questions. There is also no penalty for guessing, making it important to answer every question.

Common BCPS Preparation Mistakes to Avoid

Many candidates spend too much time memorizing isolated facts and not enough time applying them.

Avoid:

• Studying only drug mechanisms
• Ignoring renal dose adjustments
• Memorizing guidelines without understanding patient selection
• Skipping pharmacokinetic calculations
• Focusing only on your current practice specialty
• Ignoring adverse drug reactions
• Overlooking drug interactions
• Practicing only easy recall questions
• Failing to review incorrect answers
• Assuming a therapeutic laboratory value means therapy is automatically appropriate
• Confusing relative risk reduction with absolute risk reduction
• Ignoring patient-specific contraindications
• Waiting until the final week to begin timed practice

BPS explains that its examinations sample knowledge required across the major areas of responsibility identified through job analysis, rather than attempting to test every possible topic or practice setting.

How to Use This BCPS Practice Exam to Pass

Work through the questions in stages. Begin untimed so you can understand the reasoning behind each answer. Once your weak areas become clear, repeat targeted question sets and gradually introduce timed sessions.

For every incorrect answer, ask yourself:

What information did I miss?

Why was my selected option unsafe, ineffective, or less appropriate?

What patient characteristic changed the treatment decision?

That approach turns practice questions into active clinical learning instead of simple answer memorization.

Why This BCPS Practice Test Is a Useful Study Resource

This resource is designed for pharmacists who want structured practice with advanced pharmacotherapy questions, clinical case analysis, medication management, therapeutic monitoring, and board-style decision-making.

It can be used as a supplemental study resource alongside current guidelines, primary literature, pharmacotherapy references, residency-level review materials, and the official BPS Examination Content Outline. BPS does not endorse outside preparation materials, and its official sample questions are intended primarily to familiarize candidates with examination item formats rather than predict examination performance.

Prepare With Clinical Questions, Not Just Memorization

The BCPS Practice Exam 2026 gives you a structured way to test your knowledge, identify weak areas, and practice making patient-specific medication decisions before examination day.

With 775+ questions, detailed answer explanations, clinical cases, calculations, medication-safety scenarios, and broad pharmacotherapy coverage, it is built to complement a serious BCPS study plan and help you approach the examination with greater confidence and stronger clinical reasoning.

BCPS Sample Questions and Answers 

Question 1. A 67-year-old man with MRSA bacteremia is receiving vancomycin by intermittent IV infusion. His admission serum creatinine was 0.9 mg/dL, but it has increased to 1.8 mg/dL after 4 days. The pharmacist reviews two vancomycin concentrations and calculates an estimated AUC24 of 720 mg·h/L. The patient remains hemodynamically stable and cultures are now negative. Which intervention is most appropriate?

A. Increase the vancomycin dose because the infection is severe
B. Continue the current regimen because the trough concentration is therapeutic
C. Modify the vancomycin regimen to reduce exposure and minimize nephrotoxicity
D. Add gentamicin for synergistic bactericidal activity

Correct Answer: C

Answer Explanation: Option C is correct because the patient’s vancomycin exposure is excessive, with an AUC24 of 720 mg·h/L, while kidney function has substantially worsened. Contemporary vancomycin therapeutic drug monitoring generally targets an AUC24/MIC of approximately 400–600 for serious MRSA infections when the MIC is assumed to be 1 mg/L. Exposure above the recommended range is associated with increased nephrotoxicity without providing a demonstrated therapeutic advantage. The pharmacist should reassess dosing using the patient’s changing renal function and adjust the regimen accordingly. Simply relying on a trough concentration can be misleading because trough-only monitoring does not directly characterize total exposure. Adding another nephrotoxic agent would further increase risk without a clear indication in a clinically improving patient.

Tip: When renal function changes during vancomycin therapy, reassess both drug exposure and dosing interval rather than relying on a previous concentration.

Question 2. A 72-year-old woman with heart failure with reduced ejection fraction has an LVEF of 30%, sinus rhythm, and persistent NYHA class II symptoms. Current medications include carvedilol, sacubitril/valsartan, spironolactone, and dapagliflozin. Her blood pressure is 108/68 mmHg, potassium is 4.5 mEq/L, and eGFR is 52 mL/min/1.73 m². She has no history of atrial fibrillation. Which additional therapy should the pharmacist recommend specifically for mortality reduction?

A. Digoxin
B. Ivabradine
C. Apixaban
D. No additional mortality-directed medication is routinely indicated

Correct Answer: D

Answer Explanation: Option D is correct because the patient is already receiving the four major guideline-directed medication classes associated with improved outcomes in HFrEF: an ARNI, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor. Ivabradine is generally considered for selected patients who remain symptomatic with sinus rhythm and a sufficiently elevated resting heart rate despite maximally tolerated beta-blocker therapy; the case does not provide that indication. Digoxin may reduce hospitalizations in selected patients but does not provide the same mortality benefit. Anticoagulation is not indicated solely for HFrEF in sinus rhythm without another thromboembolic indication. The pharmacist should therefore avoid unnecessary therapy and continue optimization of the established regimen.

Tip: For HFrEF cases, first identify whether the patient is already receiving the four foundational medication classes before adding another drug.

Question 3. A 59-year-old woman with type 2 diabetes and stage 4 chronic kidney disease has an A1C of 8.7%. Her medications are metformin 500 mg twice daily and basal insulin. Her eGFR is 27 mL/min/1.73 m². She has obesity and established albuminuric CKD. Which intervention offers an appropriate strategy for improving glycemic control while providing additional kidney and cardiovascular benefit?

A. Increase metformin to 1,000 mg twice daily
B. Add an SGLT2 inhibitor with demonstrated CKD benefit, if otherwise appropriate
C. Replace basal insulin with glyburide
D. Add pioglitazone as the preferred renal-protective agent

Correct Answer: B

Answer Explanation: Option B is correct because SGLT2 inhibitors with demonstrated kidney and cardiovascular benefits are an important component of therapy for many patients with type 2 diabetes and CKD, including patients whose eGFR is below the threshold required for their glucose-lowering effect to be substantial. Their renal and cardiovascular benefits extend beyond A1C reduction. Increasing metformin is inappropriate because metformin should not be initiated or continued at full dosing when kidney function is severely reduced, and glyburide carries substantial hypoglycemia risk in CKD. Pioglitazone does not provide the same established kidney-protective role and may cause weight gain and fluid retention, making it particularly unattractive in a patient with significant cardiovascular risk.

Tip: Separate the glucose-lowering effect of a drug from its cardiorenal outcome benefits when evaluating diabetes therapy in CKD.

Question 4. A 64-year-old man is admitted with septic shock caused by a suspected gram-negative bloodstream infection. Blood cultures are pending. He has received appropriate IV fluid resuscitation and requires norepinephrine to maintain a mean arterial pressure of 67 mmHg. His serum creatinine has doubled from baseline. Which pharmacokinetic change is most important for the pharmacist to consider when optimizing an antimicrobial regimen during the early phase of critical illness?

A. Assume all renally eliminated drugs require immediate dose reduction
B. Consider altered volume of distribution and changing renal clearance when selecting loading and maintenance doses
C. Avoid loading doses because they increase toxicity in critically ill patients
D. Use only serum creatinine to estimate current antimicrobial exposure

Correct Answer: B

Answer Explanation: Option B is correct because critical illness can produce major changes in pharmacokinetics, including increased or unpredictable volume of distribution from fluid resuscitation, capillary leak, hypoalbuminemia, and altered tissue perfusion. Renal clearance can also change rapidly, with either acute kidney injury or augmented renal clearance occurring depending on the clinical situation. Consequently, a loading dose may need to be based primarily on the desired concentration and volume of distribution rather than reduced simply because serum creatinine is abnormal. Maintenance dosing should then incorporate the patient’s evolving clearance. Serum creatinine alone is an imperfect real-time marker of renal drug clearance during rapidly changing critical illness.

Tip: In critical care, think separately about loading dose = volume of distribution and maintenance dose = clearance.

Question 5. A 45-year-old woman with asthma uses albuterol several times daily and reports nighttime symptoms twice weekly. She currently uses an inhaled corticosteroid only when symptoms occur. Her technique is correct, and she reports no difficulty obtaining medication. Which intervention is most appropriate?

A. Continue as-needed albuterol alone
B. Discontinue inhaled corticosteroid therapy
C. Initiate an evidence-based inhaled corticosteroid-containing regimen and reduce reliance on short-acting bronchodilator therapy
D. Start chronic oral prednisone

Correct Answer: C

Answer Explanation: Option C is correct because frequent symptoms and nighttime awakenings indicate inadequate asthma control, while reliance on short-acting beta2-agonist therapy alone does not adequately address the underlying airway inflammation. Contemporary asthma management emphasizes an inhaled corticosteroid-containing strategy rather than treatment centered exclusively on SABA use. The exact regimen should be selected according to symptom frequency, exacerbation history, prior response, inhaler availability, and the applicable asthma treatment framework. Chronic systemic corticosteroids are inappropriate for routine management because of substantial long-term toxicity. Before escalating therapy, the pharmacist should also verify adherence, inhaler technique, triggers, comorbidities, and access barriers, but the case specifically establishes that technique and medication access are not the primary problems.

Tip: Persistent asthma symptoms should prompt assessment of controller therapy, not simply repeated escalation of rescue inhaler use.

Question 6. A 70-year-old patient with atrial fibrillation takes warfarin with a stable INR of approximately 2.5. He is prescribed trimethoprim-sulfamethoxazole for a urinary tract infection. Three days later, his INR is 5.2 without bleeding. Which pharmacist intervention is most appropriate?

A. Increase the warfarin dose because infection increases clotting risk
B. Recognize the interaction, reassess anticoagulation, and coordinate appropriate management of the elevated INR
C. Add aspirin to reduce thromboembolic risk
D. Continue both drugs without monitoring because the interaction is clinically insignificant

Correct Answer: B

Answer Explanation: Option B is correct because trimethoprim-sulfamethoxazole can substantially increase warfarin anticoagulant effect through pharmacokinetic and pharmacodynamic mechanisms, including inhibition of warfarin metabolism and reduction of vitamin K-producing intestinal flora. The patient’s INR of 5.2 represents clinically important over-anticoagulation even though he has no active bleeding. Management should include prompt reassessment of warfarin therapy, consideration of temporary interruption and appropriate vitamin K management based on the degree of INR elevation and bleeding risk, and selection of an alternative antibiotic when clinically feasible. Adding aspirin would increase bleeding risk without treating the underlying interaction. Continued unmonitored therapy is unsafe.

Tip: When a high-risk interaction occurs, address both the interacting medication and the immediate clinical consequence.

Question 7. A 68-year-old man taking sertraline for depression develops severe agitation, diaphoresis, diarrhea, hyperreflexia, inducible clonus, and a temperature of 38.9°C after linezolid is started for pneumonia. Which diagnosis best explains the presentation?

A. Neuroleptic malignant syndrome
B. Serotonin syndrome
C. Anticholinergic toxicity
D. Malignant hyperthermia

Correct Answer: B

Answer Explanation: Option B is correct because the combination of sertraline and linezolid can precipitate serotonin toxicity because linezolid has monoamine oxidase–inhibiting activity. The clinical pattern is particularly characteristic of serotonin syndrome, with acute mental-status changes, autonomic instability, gastrointestinal symptoms, hyperreflexia, and clonus. Neuroleptic malignant syndrome typically develops more gradually and is associated with severe rigidity and hyporeflexia after exposure to dopamine antagonists or withdrawal of dopaminergic therapy. Anticholinergic toxicity generally produces dry skin, urinary retention, mydriasis, and decreased bowel activity rather than prominent clonus and hyperreflexia. The pharmacist should recognize the interaction urgently and support discontinuation of serotonergic contributors while the patient receives appropriate medical management.

Tip: Clonus and hyperreflexia strongly favor serotonin toxicity over neuroleptic malignant syndrome.

Question 8. A 58-year-old woman with bipolar disorder is stable on lithium 900 mg/day. She develops vomiting and diarrhea for 2 days and continues taking lithium. On admission, lithium concentration is 2.1 mEq/L, creatinine has increased from 0.9 to 1.7 mg/dL, and she has coarse tremor, ataxia, and confusion. Which intervention is most appropriate?

A. Give the next lithium dose early to prevent withdrawal
B. Hold lithium and initiate urgent evaluation and management of lithium toxicity
C. Add hydrochlorothiazide to increase lithium elimination
D. Increase sodium restriction to reduce lithium exposure

Correct Answer: B

Answer Explanation: Option B is correct because the patient has symptomatic lithium toxicity accompanied by an elevated serum concentration and acute kidney injury. Gastrointestinal fluid losses can reduce renal perfusion and lithium clearance, causing accumulation. Neurologic manifestations such as coarse tremor, ataxia, and confusion are concerning for clinically significant toxicity. Lithium should be withheld while the patient receives urgent medical evaluation, including serial concentrations, renal function assessment, electrolyte monitoring, and supportive management. Severe poisoning may require extracorporeal treatment depending on the clinical picture, concentration, kidney function, and response to supportive care. Thiazide diuretics decrease lithium clearance and can increase serum lithium concentrations, making hydrochlorothiazide inappropriate.

Tip: Lithium toxicity is driven by both serum concentration and clinical symptoms; neurologic findings deserve immediate attention.

Question 9. A 76-year-old patient is discharged after hospitalization for heart failure. Before admission, the patient was taking lisinopril, furosemide, metoprolol succinate, and potassium chloride. During hospitalization, sacubitril/valsartan and spironolactone were initiated, and lisinopril was discontinued. Which medication-related action is most important during discharge reconciliation?

A. Restart lisinopril with sacubitril/valsartan
B. Ensure an appropriate washout period occurred between lisinopril and sacubitril/valsartan and verify the final medication list
C. Automatically discontinue furosemide
D. Add potassium supplementation regardless of laboratory results

Correct Answer: B

Answer Explanation: Option B is correct because concomitant administration of an ACE inhibitor and sacubitril/valsartan increases the risk of angioedema. A washout period is required when switching from an ACE inhibitor to sacubitril/valsartan. Medication reconciliation at transitions of care should therefore verify that lisinopril has actually been discontinued, that the required interval has elapsed, and that the patient understands which medications to take after discharge. Potassium supplementation should not be continued automatically because spironolactone and sacubitril/valsartan can affect potassium concentrations. Furosemide may remain necessary for volume management and should be assessed based on congestion and clinical status rather than discontinued automatically.

Tip: Transitions of care are high-risk points for duplicate therapy, omitted therapy, and contraindicated combinations.

Question 10. A 62-year-old woman with metastatic breast cancer develops severe nausea and vomiting after chemotherapy despite receiving a serotonin 5-HT3 receptor antagonist and dexamethasone. Her next chemotherapy regimen is classified as highly emetogenic. Which additional strategy is most appropriate for prevention during the next cycle?

A. Use a dopamine antagonist alone after symptoms develop
B. Add an NK1 receptor antagonist as part of a guideline-concordant multidrug antiemetic regimen
C. Stop dexamethasone because corticosteroids have no antiemetic role
D. Use metoclopramide alone before chemotherapy

Correct Answer: B

Answer Explanation: Option B is correct because highly emetogenic chemotherapy generally requires prophylactic combination antiemetic therapy targeting different pathways rather than relying on treatment after nausea begins. An NK1 receptor antagonist is an important component of prevention for many highly emetogenic chemotherapy regimens and is typically combined with other appropriate agents according to the chemotherapy regimen and patient-specific factors. Dopamine antagonists may be useful as rescue or adjunctive therapy but are not an adequate substitute for comprehensive prophylaxis in a patient with previous breakthrough symptoms. Dexamethasone has an established role in chemotherapy-induced nausea and vomiting prevention. Metoclopramide alone is insufficient for this high-risk setting.

Tip: For highly emetogenic chemotherapy, think prevention with complementary mechanisms, not rescue treatment alone.

Question 11. A 35-year-old woman presents to the emergency department 4 hours after ingesting an unknown quantity of acetaminophen. Her initial serum acetaminophen concentration plots above the treatment line on the Rumack-Matthew nomogram. AST and ALT are currently normal. Which treatment should be initiated?

A. Activated charcoal only, regardless of timing
B. N-acetylcysteine
C. Fomepizole as monotherapy
D. Sodium bicarbonate infusion

Correct Answer: B

Answer Explanation: Option B is correct because N-acetylcysteine is the antidote for potentially toxic acetaminophen exposure and is most effective when started early, although benefit may persist even when treatment is delayed. The Rumack-Matthew nomogram is used for a known single acute ingestion with a reliable ingestion time, and a concentration above the treatment threshold supports antidotal therapy. Normal aminotransferases do not exclude toxicity during the early period after ingestion. Activated charcoal may be considered in selected patients presenting soon after ingestion when the airway is protected, but it is not a substitute for N-acetylcysteine when antidotal treatment is indicated. Fomepizole is associated with toxic alcohol management, not routine acetaminophen poisoning.

Tip: In early acetaminophen toxicity, normal liver enzymes do not reassure you enough to delay antidotal therapy.

Question 12. A 79-year-old man with hypertension, osteoarthritis, and CKD stage 3b reports dizziness and two falls during the past month. His medications include amlodipine, lisinopril, hydrochlorothiazide, diphenhydramine nightly for sleep, and ibuprofen three times daily. Which intervention should the pharmacist prioritize?

A. Increase hydrochlorothiazide to improve blood pressure control
B. Continue diphenhydramine because it is available without a prescription
C. Identify and reduce medication-related fall risks, including inappropriate sedating and potentially nephrotoxic therapy
D. Add a benzodiazepine for nighttime anxiety

Correct Answer: C

Answer Explanation: Option C is correct because the patient’s falls occur in the context of multiple potentially modifiable medication risks. Diphenhydramine has strong anticholinergic effects and can contribute to sedation, confusion, impaired coordination, and falls in older adults. Chronic NSAID exposure is also concerning in CKD because it can worsen renal function and interfere with blood pressure control. The pharmacist should conduct a comprehensive medication review, assess blood pressure and orthostatic symptoms, and coordinate deprescribing or substitution where appropriate. Increasing antihypertensive therapy or adding a benzodiazepine could worsen dizziness and fall risk. This case also illustrates the importance of evaluating OTC medications rather than limiting medication reconciliation to prescription drugs.

Tip: In older adults with falls, review prescription, OTC, and PRN medications for cumulative adverse effects.

Question 13. A pharmacist evaluates a randomized controlled trial comparing Drug A with Drug B for prevention of recurrent stroke. The study reports a relative risk of 0.80 with a 95% confidence interval of 0.62–1.04. Which interpretation is most accurate?

A. Drug A significantly reduces recurrent stroke because the relative risk is below 1
B. Drug A is proven equivalent to Drug B because the confidence interval is narrow
C. The study does not demonstrate a statistically significant difference because the confidence interval includes 1.0
D. Drug B significantly increases recurrent stroke because the relative risk is 0.80

Correct Answer: C

Answer Explanation: Option C is correct because for a relative risk, the null value is 1.0. Although the point estimate of 0.80 suggests a possible 20% relative reduction in recurrent stroke with Drug A, the 95% confidence interval extends from 0.62 to 1.04 and therefore crosses the null value. The result is not statistically significant at the conventional 0.05 level. The pharmacist should also consider the absolute risk reduction, confidence interval width, study population, outcome definition, duration, and applicability to the patient rather than interpreting the relative risk alone. A nonsignificant result does not prove equivalence; an equivalence or noninferiority design would require specific methodology and prespecified margins.

Tip: For RR or OR, remember: 1 = no difference. A confidence interval crossing 1 generally means statistical significance has not been demonstrated.

Question 14. A hospital pharmacy department introduces an electronic alert recommending renal dose adjustment for selected antimicrobials. After implementation, the pharmacist notices that clinicians override the alert in 78% of cases. Review shows that many alerts are triggered for patients whose renal function does not actually require adjustment. Which quality-improvement strategy is most appropriate?

A. Increase the number of alerts to ensure clinicians see them
B. Remove all renal dosing decision support permanently
C. Analyze override patterns and redesign the alert to improve specificity and clinical relevance
D. Require pharmacists to manually approve every antimicrobial order

Correct Answer: C

Answer Explanation: Option C is correct because a high override rate can indicate alert fatigue or poor specificity rather than simply poor clinician adherence. The appropriate quality-improvement approach is to examine which alerts are being overridden, determine why, and redesign the clinical decision-support rule so that alerts appear when meaningful intervention is actually required. Possible improvements include refining renal-function thresholds, incorporating current laboratory data, excluding appropriate exceptions, and improving the wording or timing of alerts. Increasing alert volume would likely worsen alert fatigue. Completely removing decision support eliminates a potentially valuable safety intervention. Requiring manual pharmacist approval for every antimicrobial order could create unnecessary workload without addressing the underlying design problem.

Tip: Good clinical decision support should produce actionable alerts at the right time, not the maximum number of alerts.

Question 15. A hospital pharmacist is reviewing a proposed formulary change from Drug X to Drug Y. Drug Y costs $1,200 per treatment course compared with $1,000 for Drug X. In a randomized trial, Drug Y produced a 10% absolute reduction in treatment failure. The pharmacy and therapeutics committee asks whether the higher acquisition cost is justified. Which analysis would best compare the additional cost with the additional clinical benefit?

A. Cost-minimization analysis
B. Cost-effectiveness analysis
C. Cost-of-illness analysis only
D. Descriptive drug utilization review

Correct Answer: B

Answer Explanation: Option B is correct because cost-effectiveness analysis compares the incremental cost of an intervention with its incremental clinical benefit, such as treatment failures avoided, life-years gained, or another meaningful health outcome. In this case, Drug Y has a higher acquisition cost but produces a measurable improvement in treatment success, so the relevant question is whether the additional cost is reasonable relative to the additional clinical benefit. Cost-minimization analysis is appropriate only when competing interventions have equivalent outcomes. Cost-of-illness analysis estimates the overall economic burden of a disease rather than comparing competing treatment strategies. Drug utilization review evaluates medication use patterns and appropriateness but does not by itself quantify incremental cost relative to incremental clinical benefit.

Tip: If two therapies have different clinical outcomes, think cost-effectiveness, not cost-minimization.